Limited economic evidence for vitiligo treatments

Limited economic evidence for vitiligo treatments

(HealthDay)—The cost burden associated with vitiligo is high, although no evidence exists for the value of vitiligo treatments, according to a research letter published online Aug. 10 in the British Journal of Dermatology.

Emma McManus, Ph.D., from the University of East Anglia in the United Kingdom, and colleagues conducted a to examine all economic evidence related to , assess the quality of this economic research, and identify gaps in the research.

The researchers identified two published research papers with a primary economic objective. The first was a willingness-to-pay survey conducted among 1,023 German vitiligo patients who were asked how much they were willing to pay for a cure. Overall, 32.5 percent of the patients stated that they would be prepared to pay a one-off investment of more than €5,000 (2006 price year; the highest band offered) for a cure of vitiligo. In a second study, the annual direct cost of treating vitiligo was estimated at $175,000,000 for 2004 price year (equivalent to £151,935,027.49 in 2016), which included visits to clinicians, hospital appointments, and prescriptions.

"The systematic review does not enable us to answer our title question; it shows that no evidence exists to support or refute the value for money afforded by vitiligo treatments from any perspective (health systems, employers, or individuals)," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: British Journal of Dermatology

Copyright © 2017 HealthDay. All rights reserved.

Citation: Limited economic evidence for vitiligo treatments (2017, August 17) retrieved 29 March 2024 from https://medicalxpress.com/news/2017-08-limited-economic-evidence-vitiligo-treatments.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Atopic dermatitis linked to risk of alopecia areata, vitiligo

0 shares

Feedback to editors